Browsing by Author "Koraćević, Goran (24341050000)"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Etiology, Predisposing Factors, Clinical Features and Diagnostic Procedure of Otomycosis: A Literature Review(2023) ;Bojanović, Mila (33567602100) ;Stalević, Marko (57218167216) ;Arsić-Arsenijević, Valentina (6507940363) ;Ignjatović, Aleksandra (54395417600) ;Ranđelović, Marina (57188926826) ;Golubović, Milan (57207817323) ;Živković-Marinkov, Emilija (35492065100) ;Koraćević, Goran (24341050000) ;Stamenković, Bojana (16418105500)Otašević, Suzana (57218861105)Otomycosis (OM) is a superficial fungal infection of the external auditory canal (EAC) with a worldwide prevalence ranging from 9% to 30%. Commonly, otomycoses are caused by Aspergillus (A.) niger complex and Candida spp. Other causative agents are yeasts of the genera Cryptococcus spp., Rhodotorula spp., Geotrichum candidum, dermatophytes (Trichophyton mentagrophytes), and non-dermatophytes molds (Fusarium spp., Penicillium spp., Mucorales fungi). The widest range of different species causing OM are found in the territories of Iran, India, China, Egypt, Mexico, and Brazil. Fungal infection of the EAC varies from mild to severe forms. It can be acute, subacute, or chronic, and is often unilateral, while the bilateral form is more common in immunocompromised patients. From an epidemiological point of view, tropical and subtropical climates are the most significant risk factor for the development of otomycosis. Other predisposing conditions include clothing habits, EAC hygiene practices, long-term antibiotic therapy, diabetes, and immunodeficiency. Since it is often difficult to distinguish otomycosis from an infection of a different origin, laboratory-based evidence, including standard procedures (microscopy and cultivation), is essential for diagnosis. For the treatment of this superficial fungal infection, there are no official therapeutic guidelines and protocols. However, many antifungals for local application, such as polyene, imidazoles, and allylamines, can be applied, as well as systemic antimycotics (triazoles) in severe forms of infection. © 2023 by the authors. - Some of the metrics are blocked by yourconsent settings
Publication Etiology, Predisposing Factors, Clinical Features and Diagnostic Procedure of Otomycosis: A Literature Review(2023) ;Bojanović, Mila (33567602100) ;Stalević, Marko (57218167216) ;Arsić-Arsenijević, Valentina (6507940363) ;Ignjatović, Aleksandra (54395417600) ;Ranđelović, Marina (57188926826) ;Golubović, Milan (57207817323) ;Živković-Marinkov, Emilija (35492065100) ;Koraćević, Goran (24341050000) ;Stamenković, Bojana (16418105500)Otašević, Suzana (57218861105)Otomycosis (OM) is a superficial fungal infection of the external auditory canal (EAC) with a worldwide prevalence ranging from 9% to 30%. Commonly, otomycoses are caused by Aspergillus (A.) niger complex and Candida spp. Other causative agents are yeasts of the genera Cryptococcus spp., Rhodotorula spp., Geotrichum candidum, dermatophytes (Trichophyton mentagrophytes), and non-dermatophytes molds (Fusarium spp., Penicillium spp., Mucorales fungi). The widest range of different species causing OM are found in the territories of Iran, India, China, Egypt, Mexico, and Brazil. Fungal infection of the EAC varies from mild to severe forms. It can be acute, subacute, or chronic, and is often unilateral, while the bilateral form is more common in immunocompromised patients. From an epidemiological point of view, tropical and subtropical climates are the most significant risk factor for the development of otomycosis. Other predisposing conditions include clothing habits, EAC hygiene practices, long-term antibiotic therapy, diabetes, and immunodeficiency. Since it is often difficult to distinguish otomycosis from an infection of a different origin, laboratory-based evidence, including standard procedures (microscopy and cultivation), is essential for diagnosis. For the treatment of this superficial fungal infection, there are no official therapeutic guidelines and protocols. However, many antifungals for local application, such as polyene, imidazoles, and allylamines, can be applied, as well as systemic antimycotics (triazoles) in severe forms of infection. © 2023 by the authors. - Some of the metrics are blocked by yourconsent settings
Publication Less Known but Clinically Relevant Comorbidities of Atrial Fibrillation: A Narrative Review(2022) ;Koraćević, Goran (24341050000) ;Stojković, Milan (57986907500) ;Stojanović, Milovan (57188923072) ;Zdravković, Marija (24924016800) ;Simić, Dragan (57212512386) ;Šalinger-Martinović, Sonja (15052251700) ;Đorđević, Dragan (7006039370) ;Damjanović, Miodrag (24801926700) ;Đorđević-Radojković, Danijela (18133713200)Koraćević, Maja (36188111200)Background: The important risk factors for atrial fibrillation (AF) in the general population are not always equally important in specific and relatively prevalent diseases. Objective: The main goal of this narrative review is to focus attention on the presence and the relationship of AF with several important diseases, such as cancer or sepsis, in order to: 1) stimulate further research in the field, and 2) draw attention to this relationship and search for AF in clinical practice. Methods: We searched PubMed, SCOPUS, Elsevier, Wiley, Springer, Oxford Journals, Cambridge, SAGE, and Google Scholar for less-known comorbidities of AF. The search was limited to publications in English. No time limits were applied. Results: AF is widely represented in cardiovascular and other important diseases, even in those in which AF is rarely mentioned. In some specific clinical subsets of AF patients (e.g., patients with sepsis or cancer), the general risk factors for AF may not be so important. Patients with new-onset AF have a several-fold increase in relative risk of cancer, deep vein thrombosis, and pulmonary thromboembolism (PTE) during the follow-up. Conclusion: AF presence, prognosis, and optimal therapeutic approach are insufficiently recognised in several prevalent diseases, including life-threatening ones. There is a need for a better search for AF in PTE, pulmonary oedema, aortic dissection, sepsis, cancer and several gastrointestinal diseases. Im-proved AF detection would influence treatment and improve outcomes. © 2022 Bentham Science Publishers. - Some of the metrics are blocked by yourconsent settings
Publication Single prognostic cut-off value for admission glycemia in acute myocardial infarction has been used although high-risk stems from hyperglycemia as well as from hypoglycemia (a narrative review)(2020) ;Koraćević, Goran (24341050000) ;Mićić, Slađana (57212551841) ;Stojanović, Milovan (57188923072) ;Tomašević, Miloje (57196948758) ;Kostić, Tomislav (26023450500) ;Koraćević, Maja (36188111200)Janković, Irena (35848631200)All original articles and meta-analysis use the single cut-off value to distinguish high-risk hyperglycemic from other acute myocardial infarction (AMI) patients. The mortality rate is 3.9 times higher in non-diabetic AMI patients with admission glycemia ≥6.1 mmol compared to normoglycemic non-diabetic AMI patients. On the other hand, admission hypoglycemia in AMI is an important predictor of mortality. Because both admission hypo- and hyperglycemia correspond to higher in-hospital mortality, this graph is recognized as “J or U shaped curve”. The review suggests two cut-off values for admission glycemia for risk assessment in AMI instead of single one because hypoglycemia as well as hyperglycemia represents a high-risk factor. © 2020 Primary Care Diabetes Europe - Some of the metrics are blocked by yourconsent settings
Publication Single prognostic cut-off value for admission glycemia in acute myocardial infarction has been used although high-risk stems from hyperglycemia as well as from hypoglycemia (a narrative review)(2020) ;Koraćević, Goran (24341050000) ;Mićić, Slađana (57212551841) ;Stojanović, Milovan (57188923072) ;Tomašević, Miloje (57196948758) ;Kostić, Tomislav (26023450500) ;Koraćević, Maja (36188111200)Janković, Irena (35848631200)All original articles and meta-analysis use the single cut-off value to distinguish high-risk hyperglycemic from other acute myocardial infarction (AMI) patients. The mortality rate is 3.9 times higher in non-diabetic AMI patients with admission glycemia ≥6.1 mmol compared to normoglycemic non-diabetic AMI patients. On the other hand, admission hypoglycemia in AMI is an important predictor of mortality. Because both admission hypo- and hyperglycemia correspond to higher in-hospital mortality, this graph is recognized as “J or U shaped curve”. The review suggests two cut-off values for admission glycemia for risk assessment in AMI instead of single one because hypoglycemia as well as hyperglycemia represents a high-risk factor. © 2020 Primary Care Diabetes Europe - Some of the metrics are blocked by yourconsent settings
Publication Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy(2025) ;Koraćević, Goran (24341050000) ;Stojanović, Milovan (57188923072) ;Zdravković, Marija (24924016800) ;Janković Tomasević, Ruzica (55246100200) ;Ćirić Zdravković, Snežana (56427994000) ;Božinović, Nenad (56614042000) ;Cvetković, Predrag (57188930156) ;Pavlović, Milorad (57201659222)Pavlović, Dimitrije (57701387500)Introduction: Hypertensive left ventricular hypertrophy (HTN LVH) is a highly prevalent high-risk condition, and the recommendations for HTN LVH treatment are essentially unchanged for several decades. Areas covered: The current therapeutic approach to HTN LVH is to choose antihypertensive drugs according to their ability to reverse left ventricular (LV) remodeling. On the other hand, for the majority arterial hypertension (HTN) patients we should start treatment with a combination of different antihypertensive drugs. Therefore, the goal of antihypertensive treatment of HTN LVH should be adapted to the current recommendation in other parts of guidelines. The recommendation we need is not only which individual drug, but rather which combination of two antihypertensive agents is optimal for reversed LV remodeling. Expert opinion: In this paper, we pointed out that treatment recommendation for HTN LVH can be updated in a similar way as therapy for the whole HTN population–by recommending a combination of two or three antihypertensives in a single pill. Clinicians should be directly advised what is the first- and what the second-line combination of antihypertensives for HTN LVH in evidence-based medicine. Therefore, we suggest that combination treatment should be studied, compared and then recommended also for very prevalent higher-risk HTN LVH patients. © 2025 Informa UK Limited, trading as Taylor & Francis Group.
